Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 5—May 2017

Research

Use of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April–August 2016

Michelle S. ChevalierComments to Author , Brad J. Biggerstaff, Sridhar V. Basavaraju, M. Cheryl Bañez Ocfemia, Jose O. Alsina, Consuelo Climent-Peris, Robin R. Moseley, Koo-Whang Chung, Brenda Rivera-García, Melissa Bello-Pagán, Lisa L. Pate, Susan A. Galel, Phillip Williamson, and Matthew J. Kuehnert
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.S. Chevalier, S.V. Basavaraju, M.C. Bañez Ocfemia, R.R. Moseley, K.-W. Chung, M.J. Kuehnert); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (B.J. Biggerstaff); Banco de Sangre de Servicios Mutuos, San Juan, Puerto Rico (J.O. Alsina); Banco de Sangre del Centro Medico of the Administración de Servicios Médicos, San Juan (C. Climent-Peris); Puerto Rico Department of Health, San Juan (B. Rivera-García, M. Bello-Pagán); Roche Molecular Systems, Inc., Pleasanton, California, USA (L.L. Pate, S.A. Galel); Creative Testing Solutions, Tempe, Arizona, USA (P. Williamson)

Main Article

Table 2

Sensitivity analysis for Zika virus infections, computed from BSIS and ASEM cobas Zika ID-NAT results, Puerto Rico, April 3–August 12, 2016*

Mean viremia duration, d Total no. infections (95% CI) Population infected, % (95% CI)
7 684,937 (585,924–816,000) 18.82 (16.1–22.43)
14 323,525 (276,756–385,431) 8.89 (7.61–10.59)
21 214,563 (183,546–255,619) 5.89 (5.04–7.02)

*Data for August 1–August 12, 2016 available only for BSIS. cobas Zika, Roche Molecular Systems, Inc., Pleasanton, CA, USA. ASEM, Banco de Sangre del Centro Médico de la Administración de Servicios Médicos; BSIS, Banco de Sangre de Servicios Mutuos; ID-NAT, individual nucleic acid testing.

Main Article

TOP